# A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

> **NCT01496170** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 32 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MK-8931
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01496170
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01496170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01496170, "A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01496170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*